However, cytokine release syndrome (CRS) and immune cell–associated neurotoxicity (ICANS), which are typically managed through IL-6R or IL-1R antagonists, remain prevalent complications, especially in patients with high burdens of disease (1). The gene discussed is IL6R; the disease is congenital rubella syndrome.